Skip to main content
Premium Trial:

Request an Annual Quote

Roche Buys Tissue Dissection Technology from AvanSci Bio

NEW YORK (GenomeWeb) – Roche Diagnostics today announced it has signed a definitive Asset Purchase Agreement with AvanSci Bio for all products associated with the high-performance microdissection of slide mounted tissue sections.

The system comprises instrumentation, software, and consumables used by researchers and clinicians to extract specific areas of tissue for subsequent molecular analysis including real-time PCR, microarrays, and sequencing.

Financial and other details of the agreement were not disclosed.

AvanSci Bio's technology includes the automated MilliSect dissection instrument, which will be tested at customer sites in 2015. The MilliSect system enables a greater than 90 percent tumor enriched sample for molecular analysis, the firm said in a statement.

"This innovative system will expand our diagnostic tool kit allowing us to link the diagnostic hematoxylin and eosin stain with sequencing analysis through high-quality sample preparation," Dan Zabrowski, head of Roche Tissue Diagnostics and Sequencing Solutions, said in a statement. 

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.